News Details
NCCN Foundation Awards Grants to Six Young Investigators
The NCCN Foundation has awarded its sixth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
FORT WASHINGTON, PA — The NCCN Foundation® has awarded grants to six young investigators from NCCN Member Institutions. These awardees, who are dedicated to advancing and discovering new treatments for cancer, enhancing quality, and improving patient education, represent the sixth series of NCCN Foundation Young Investigator Awards—a program initiated in 2011. The grants will provide $150,000 in funding over a two-year period, beginning in July 2016.
“NCCN Foundation is committed to advancing cancer treatment by funding promising young researchers at the forefront of innovation in cancer research. We congratulate and applaud the 2016 awardees for their dedication to advancing the standard of cancer care,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation.
Following are the 2016 NCCN Foundation Young Investigator Awards recipients:
- Eli Diamond, MD, MPhil, Memorial Sloan Kettering Cancer Center, Coping with Glioblastoma: A Study of Communication for Patients, Caregivers, and Physicians
- Ryan Nipp, MD, Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Randomized Study of Perioperative Geriatric Evaluation and Management of Older Patients with Gastrointestinal Cancers Undergoing Surgical Resection
- Elias Obeid, MD, MPH, Fox Chase Cancer Center, Systemic and Tumor Immunity Predictors of Response to PD-1 Blockade with Carboplatin in Metastatic Triple-Negative Breast Cancer
- Saul Priceman, PhD, City of Hope Comprehensive Cancer Center, Immunotherapy for Prostate Cancer Combining CAR-Engineered T Cells with Targeted Checkpoint Inhibition
- Kathryn Ruddy, MD, Mayo Clinic Cancer Center, NCCN Guideline Adherence in Breast Cancer Survivors
- Daniel Sherbenou, MD, PhD, University of Colorado Cancer Center, A Patient-Derived Xenograft Model of Multiple Myeloma to Test Anti-CD46 Antibody Drug Conjugate for Curative Potential
The awardees responded to a Request for Proposals issued by the NCCN Foundation to the NCCN Member Institutions and were nominated by their institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts; the awardees were selected based on several key components, including scientific merit and study design. The studies will be managed and overseen by the NCCN Oncology Research Program (ORP).
“NCCN believes that investments in young investigators at the beginning of their careers is a powerful mechanism to ensure that the best and brightest begin their journey to a future in cancer research,” said Robert C. Young, MD, Interim Vice President, NCCN ORP.
Since their inception in 2011, NCCN Foundation has provided funding to 29 U.S. researchers through the Young Investigator Awards. On March 31, and April 1, 2016, the National Comprehensive Cancer Network® (NCCN®) featured abstracts from the fourth series of Young Investigator Awards recipients during the NCCN 21st Annual Conference General Poster Session in Hollywood, Florida.
The 2016 NCCN Foundation Young Investigator Awards were made possible through support from AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences Inc.; Pfizer, Inc.; and Takeda Oncology.
For more information about the NCCN Young Investigator Awards, visit NCCNFoundation.org.
###
About NCCN Foundation
Through philanthropy, the NCCN Foundation® empowers people through knowledge and advances the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care, so that patients can live better lives. Visit NCCNFoundation.org.